2024 World Conference on Lung Cancer (WCLC) - Posters-P2.17A.04 Cost Effectiveness of a System-Level Precision Medicine Intervention for Stage IV Non-Small Cell Lung Cancer Patients

P2.17A.04 Cost Effectiveness of a System-Level Precision Medicine Intervention for Stage IV Non-Small Cell Lung Cancer Patients

Back to course

Pdf Summary

The study investigates the cost-effectiveness of a precision medicine intervention for stage IV non-small cell lung cancer (NSCLC) using a decision analytic model at a hypothetical cancer center treating 500 patients annually. The research evaluates four strategies to enhance the use of Next Generation Sequencing (NGS) in newly diagnosed patients. The model considers costs in 2003 U.S. dollars from a healthcare system perspective, factoring in testing, treatment, and follow-up costs.<br /><br />The study highlights that the use of a PREDICT (PREcision meDICine Thoracic) system, an in-house assay and molecular tumor board (MTB) approach, despite being slightly more costly, results in improved quality-adjusted life years (QALYs), increased targeted therapy, and reduced chemotherapy reliance. Specifically, focusing NGS on patients with non-squamous histology proves more cost-effective. Transitioning from send-out NGS to the PREDICT strategy yields a cost per QALY saved of $242,139 for non-squamous patients.<br /><br />Key intervention components include:<br />- A reflex in-house solid tumor-focused NGS panel (DNA/RNA hybrid).<br />- A molecular tumor board that evaluates cases.<br />- A portal for real-time sample processing updates and results.<br />- A navigator that aids in coordination.<br /><br />Results indicate a higher probability of receiving usable NGS results with PREDICT (97%) compared to send-out (79.9%). In terms of costs and outcomes across scenarios, PREDICT displays beneficial outcomes in terms of increased targeted therapy usage and improved QALY, albeit PREDICT is more costly in several scenarios.<br /><br />Overall, the precision medicine intervention using PREDICT increases the application of targeted therapies and has economic advantages, particularly in non-squamous histology cases, justifying its implementation despite a higher upfront cost.

Asset Subtitle

Johnie Rose

Meta Tag

Speaker Johnie Rose

Topic Global Health, Health Services & Health Economics

Keywords

precision medicine

cost-effectiveness

NSCLC

Next Generation Sequencing

PREDICT system

molecular tumor board

quality-adjusted life years

targeted therapy

non-squamous histology

economic advantages